Sandra Ortiz-Cuaran
Overview
Explore the profile of Sandra Ortiz-Cuaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortiz-Cuaran S, Leonce C
Clin Cancer Res
. 2025 Jan;
PMID: 39808501
The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent HER3 activation constitutes a...
2.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39694415
Objectives: Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI)...
3.
Bouhamama A, Leporq B, Faraz K, Foy J, Boussageon M, Perol M, et al.
Front Radiol
. 2023 Jul;
3:1168448.
PMID: 37492391
Introduction: In this study, we aim to build radiomics and multiomics models based on transcriptomics and radiomics to predict the response from patients treated with the PD-L1 inhibitor. Materials And...
4.
Muller N, Lorenz C, Ostendorp J, Heisel F, Friese U, Cartolano M, et al.
Cancer Res
. 2023 Jun;
83(15):2471-2479.
PMID: 37289018
Significance: Unraveling the trajectories of preexisting resistant and drug-tolerant persister cells facilitates the rational design of multidrug combination or sequential therapies, presenting an approach to explore for treating EGFR-mutant lung...
5.
Blaquier J, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona A, Recondo G
Clin Cancer Res
. 2023 Apr;
29(18):3579-3591.
PMID: 37093192
The current landscape of targeted therapies directed against oncogenic driver alterations in non-small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can derive significant benefit from EGFR tyrosine...
6.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al.
Data Brief
. 2022 Sep;
44:108556.
PMID: 36111282
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who...
7.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al.
Eur J Cancer
. 2022 Aug;
174:287-298.
PMID: 36038492
Introduction: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC)...
8.
Dongre A, Ortiz-Cuaran S, Korkaya H
Front Immunol
. 2022 Jun;
13:940164.
PMID: 35707530
No abstract available.
9.
Ortiz-Cuaran S, Swalduz A, Foy J, Marteau S, Morel A, Fauvet F, et al.
Eur J Cancer
. 2022 May;
169:106-122.
PMID: 35550950
Introduction: Epithelial-to-mesenchymal transition (EMT) is associated with tumor aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) and other cancers. The identification of immune-checkpoint ligands (ICPLs) associated...
10.
Desage A, Leonce C, Swalduz A, Ortiz-Cuaran S
Front Oncol
. 2022 Mar;
12:796832.
PMID: 35251972
Although activating mutations represent the most common oncogenic driver in non-small cell lung cancer (NSCLC), various attempts to inhibit failed in the past decade. mutations are associated with a poor...